SCHEMBL4253373

SCHEMBL4253373

CCOC(=O)c1c(C)cc(OCC)nc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
CYP3A4 P08684 3/20 0.49
TDP1 Q9NUW8 1/20 0.49
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 3/20 0.48
GAA P10253 3/20 0.48
HPGD P15428 2/20 0.48
RAB9A P51151 2/20 0.48
LMNA P02545 2/20 0.48
NPC1 O15118 1/20 0.48
MAPT P10636 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HTT P42858 1/20 0.46
NR1H2 P55055 1/20 0.45
NR1H3 Q13133 1/20 0.45
ADORA3 P0DMS8 2/20 0.44
PDE4D Q08499 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
USP2 O75604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16774397 0.86 POLB (0.46) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL13611414 0.85 MAPT (0.42) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL7362801 0.81 POLB (0.60) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL9523494 0.80 ALDH1A1 (0.53) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL1296287 0.80 CYP3A4 (0.56) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL3277897 0.79 SMN1; SMN2 (0.50) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL13934247 0.79 SMN1; SMN2 (0.50) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL22453926 0.79 SMN1; SMN2 (0.52) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL1085394 0.79 SMN1; SMN2 (0.50) POLBSMN1; SMN2CYP3A4TDP1KDM4E
SCHEMBL22454038 0.77 SMN1; SMN2 (0.49) POLBSMN1; SMN2CYP3A4TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
EP-2044055-A2 AMIDE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2009-04-08 EP disclosed
WO-2008011131-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 WO disclosed
WO-2008011131-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286791-A1 Amide Compounds DLAT, DGAT2, DGAT1 POLB 2102/4885SMN1; SMN2 2456/4885CYP3A4 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.